When to suspect TTP?
TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.
Bekijk meer
Verworven trombotische trombocytopenie purpura (attp)
Voor zorgverleners
What is TTP? A rare, life-threatening medical emergency
Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.
Bekijk meer
Signs and symptoms of aTTP
Know the signs and symptoms of acquired TTP (aTTP).
Bekijk meer
Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications. Caplacizumab is an innovative nanobody® and cornerstone in the treatment of iTTP.1 This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.2
Bekijk meer
Algemene informatie over TTP
Op deze pagina vindt u uitgebreide informatie over TTP. Wat er gebeurt in het lichaam en hoe TTP ontstaat.
Bekijk meer